BioDuro, a global CRO leader focused on preclinical chemistry, biology, and fully outsourced integrated drug development services for pharmaceutical partners, merged its US operations with Formex, a leader in pharmaceutical API formulation, development and cGMP manufacturing, with turnkey 44,000 square foot manufacturing facility in San Diego, California.

Under the terms of the agreement, the combined companies will operate under the corporate structure of BioDuro headquartered in San Diego, California. The formulation and manufacturing group at Formex will continue to operate in San Diego, as a wholly-owned subsidiary of BioDuro.

BioDuro's global operations include a 100,000 square foot facility in Beijing, focused largely on biosimilars, synthetic, medicinal and computational chemistry, and a 92,000 sf state of the art facility in Shanghai, that houses BioDuro's drug screening, DMPK, and integrated biology, as well as GLP bioanalysis, PK/PD, biomarker and translational research.

With the addition of Formex, BioDuro gains access to a 44,000 square foot cGMP manufacturing facility in San Diego, with proven expertise in formulation, development, and manufacture of drug product, using advanced and proprietary technologies to enhance bioavailability of poorly soluble compounds, and provide seamless translation of high value clinical candidates developed by BioDuro's preclinical group, into more efficacious clinical trial material.